Article Figures & Data
Figures
- FIGURE 1.
A 14-y-old boy with thoracic high-grade chondroblastic osteosarcoma. (A) Radiograph shows osteolytic destruction of seventh rib. (B) MR image shows inhomogeneous uptake of gadolinium–diethylenetriaminepentaacetic acid within primary lesion and highly vascularized tumor satellite adjacent to diaphragm. (C) PET image before neoadjuvant chemotherapy shows inhomogeneous FDG uptake in primary lesion (T/B, 10.3) and homogeneous hypermetabolism of satellite (T/B, 11.7).
- FIGURE 2.
A 32-y-old woman with stage 3 giant cell tumor of tibial head. (A) Radiograph shows radiolucent, ill-defined lesion located eccentrically in epiphysis and adjacent metaphyseal region with destruction of dorsomedial cortex. (B) MR image shows homogeneous uptake of gadolinium–diethylenetriaminepentaacetic acid within lesion and tumoral infiltration of popliteus muscle. (C) PET image shows highly hypermetabolic lesion suggestive of malignant tumor (T/B, 35.0). (D) Gross specimen shows subchondral extension, cortical destruction, and typical hemorrhagic aspect of giant cell tumor.
- FIGURE 3.
A 10-y-old girl with low-grade periosteal osteosarcoma of femur. (A) Angiogram shows moderate vascularization, saucerization of adjacent cortex, and radiating spicules. (B) MR image shows tumor located at external surface of bone without involvement of marrow cavity. (C) Bone scintigram shows hypermetabolic diaphyseal lesion without anatomic details. (D) PET image shows that tumor is surrounding femur (T/B, 6.1) and that medullary cavity is without elevated uptake, enabling definitive exclusion of classic central osteosarcoma. (E) Gross specimen shows lesion limited to external surface of bone, without medullary penetration.
Tables
Diagnosis n Range Mean SD Median P* Osteosarcoma 44 3.3–33.2 11.1 7.2 9.1 <0.001 Ewing's sarcoma 14 4.0–31.0 7.1 7.0 5.1 <0.001 Chondrosarcoma 14 1.4–11.8 5.2 3.2 5.3 <0.01 Malignant fibrous histiocytoma 6 3.3–26.0 13.0 8.6 14.6 <0.001 Angiosarcoma 4 3.5–31.0 16.2 13.6 15.2 <0.01 Leiomyosarcoma 2 27.2–73.0 Other sarcomas 2 15.9–20.5 Chordoma 5 3.6–12.5 6.9 3.6 6.6 <0.01 Giant cell tumor 5 10.1–35.0 20.4 9.9 19.1 <0.001 Aneurysmatic bone cyst 15 1.1–5.9 3.0 1.5 2.3 NS Simple bone cyst 9 1.0–3.5 1.7 0.7 1.5 NS Chondroma 9 1.4–2.8 2.3 0.5 2.3 NS Osteochondroma 8 1.0–2.9 2.1 0.6 2.1 NS Fibrous dysplasia 4 5.2–11.5 7.4 2.8 6.5 <0.01 Nonossifying fibroma 6 1.2–18.6 6.8 6.9 4.5 NS Desmoplastic fibroma 2 2.2–7.0 Chondroblastoma 2 6.5–33.6 Osteoid osteoma 2 2.4–2.9 Chondromyxoid fibroma 1 3.0 Osteofibrous dysplasia 1 2.8 Eosinophilic granuloma 2 4.5–4.7 Parathyroid osteopathy 1 5.1 Osteomyelitis 11 1.1–24.1 5.6 7.3 2.4 NS Other tumorlike lesions 9 1.0–2.3 1.6 0.6 1.7 NS Bone metastasis 12 4.6–34.0 15.2 8.6 14.2 <0.001 Malignant lymphoma 6 3.5–49.2 21.9 16.5 18.7 <0.001 Plasmacytoma 6 1.3–15.1 8.4 5.6 9.5 <0.05 ↵* Calculated by comparison with stage 1 and 2 benign lesions.
NS = not significant.
In this issue
Jump to section
Related Articles
Cited By...
- Metastatic Mimicker in Thyroid Cancer with Thyroglobulin Elevation and an FDG-Avid Recurrent Aneurysmal Bone Cyst
- False-Positive Positron Emission Tomography in Patients With History of Malignancy
- Correlation Between Glycolytic Phenotype and Tumor Grade in Soft-Tissue Sarcomas by 18F-FDG PET
- NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
- Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine
- PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
- Imaging of Bone Sarcomas
- Diagnostic Value and Limitations of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Cartilaginous Tumors of Bone
- PET Imaging of Osteosarcoma
- Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
- Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma
- The Role of Quantitative 18F-FDG PET Studies for the Differentiation of Malignant and Benign Bone Lesions
- Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms?